ストックスクリーナーアプリを入手
11.07
3.07%
0.33
前日終値:
$10.74
開ける：
$11.5
24時間の取引高:
1.21M
Relative Volume:
1.62
時価総額：
$1.16B
収益：
$247.00M
当期純損益:
$-249.00M
株価収益率:
-3.5825
EPS:
-3.09
ネットキャッシュフロー:
$-267.00M
1週間 パフォーマンス:
-15.50%
1か月 パフォーマンス:
-21.71%
6か月 パフォーマンス:
-37.32%
1年 パフォーマンス:
-32.54%
1日の値動き範囲:
$10.81
$11.66
1週間の範囲:
$10.63
$12.97
52週間の値動き範囲:
$10.63
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
RCUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
11.07 | 1.16B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
| 2024-10-08 | 開始されました | Wells Fargo | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-11-23 | 開始されました | Evercore ISI | Outperform |
| 2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-09-27 | 開始されました | Mizuho | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2018-10-09 | 開始されました | Wedbush | Outperform |
| 2018-04-09 | 開始されました | Citigroup | Buy |
| 2018-04-09 | 開始されました | Goldman | Neutral |
| 2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
Arcus Biosciences Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Consensus Target Price from Analysts - Defense World
Arcus Biosciences appoints new Chief Medical Officer - MSN
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock - Investing.com
Gilead Sciences acquires $14.9 million in Arcus Biosciences stock By Investing.com - Investing.com Australia
Arcus Biosciences stock hits 52-week low at $10.65 By Investing.com - Investing.com Nigeria
Arcus Biosciences stock hits 52-week low at $10.65 - Investing.com India
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts - Yahoo Finance
Arcus Biosciences stock dips after pricing $150M offering - MSN
Latham & Watkins Advises Arcus Biosciences in US$150 Million Offering of Common Stock - Legal Desire News Network
Arcus Biosciences stock target cut to $18 at H.C. Wainwright By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week low at $13.48 - MSN
Arcus Biosciences stock target cut to $18 at H.C. Wainwright - Investing.com
(RCUS) Technical Pivots with Risk Controls - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry By Investing.com - Investing.com Nigeria
Arcus Biosciences sets $11/share for $150M stock offering By Investing.com - Investing.com Nigeria
Arcus Biosciences (NYSE:RCUS) Price Target Lowered to $25.00 at Morgan Stanley - Defense World
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst Downgrade - Defense World
Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out - News & Insights
Arcus Biosciences Shares Are Down Today: What's Going On? - Benzinga
Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Nigeria
Arcus stock falls as Gilead opts out cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences: Hold Rating Amid Uncertain Future for Casdatifan and Competitive Challenges - TipRanks
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan - Yahoo Finance
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg - Fierce Biotech
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com
Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com UK
Arcus Biosciences reports strong cash position, retains casdatifan rights - Investing.com
Gilead looks on as Arcus casdatifan data hints at potential - The Pharma Letter
Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market - Nasdaq
Arcus Biosciences Prices $150 Million Share Offering -February 18, 2025 at 07:34 am EST - Marketscreener.com
Arcus Biosciences reports strong cash position, retains casdatifan rights By Investing.com - Investing.com Canada
Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry - Investing.com
Arcus Biosciences sets $11/share for $150M stock offering - Investing.com India
Arcus Biosciences (RCUS) Expected to Announce Earnings on Wednesday - Defense World
Arcus Biosciences (RCUS) Retains Rights to Casdatifan, and Announces Pricing of $150 Million Common Stock Offering - StreetInsider.com
Major Cancer Drug Development: Arcus Takes Full Control of Breakthrough $5B Treatment After Gilead Exit - StockTitan
Arcus Biosciences (RCUS) Announces 13.64M Share Offering at $11/sh - StreetInsider.com
Arcus Bio Raises Massive $150M War Chest: Major Funding Boost for Cancer Drug Development - StockTitan
Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Down 22.7% in January - MarketBeat
Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Clinical Trial Success: New Kidney Cancer Drug Keeps 87% of Late-Stage Patients Disease-Free - StockTitan
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - Lelezard
Arcus Biosciences (NYSE:RCUS) Sets New 1-Year LowShould You Sell? - MarketBeat
Arcus Biosciences’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com Nigeria
Arcus Biosciences stock hits 52-week low at $12.13 - MSN
Arcus Biosciences stock hits 52-week low at $12.13 By Investing.com - Investing.com Nigeria
Arcus Appoints CMO With $4.7M Strategic Equity PackageMajor Leadership Move - StockTitan
Revolutionary Renal Cancer Drug Data: Arcus (RCUS) Unveils Clinical Results That Could Reshape Treatment Landscape - StockTitan
Is Arcus Biosciences (NYSE:RCUS) A Risky Investment? - Simply Wall St
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):